Options on MediciNova Common Stock Listed on CBOE
September 25 2016 - 7:00PM
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ
Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo
Stock Exchange (Code Number: 4875), today announced that the
Chicago Board Options Exchange (CBOE) has listed options (calls and
puts) for MediciNova common stock.
About CBOE
CBOE is the largest U.S. options exchange and the
creator of listed options. Additional information about CBOE
and its products is available at the CBOE website at
www.cboe.com.
About MediciNova
MediciNova, Inc. is a publicly-traded
biopharmaceutical company founded upon acquiring and developing
novel, small-molecule therapeutics for the treatment of diseases
with unmet medical needs with a commercial focus on the U.S.
market. MediciNova's current strategy is to focus on MN-166
(ibudilast) for neurological disorders such as progressive MS, ALS
and substance dependence (e.g., alcohol use disorder,
methamphetamine dependence and opioid dependence), and MN-001
(tipelukast) for fibrotic diseases such as NASH and IPF.
MediciNova’s pipeline also includes MN-221 (bedoradrine) for the
treatment of acute exacerbations of asthma and MN-029 (denibulin)
for solid tumor cancers. MediciNova is engaged in strategic
partnering and other potential funding discussions to support
further development of its programs. For more information on
MediciNova, Inc., please visit www.medicinova.com.
Statements in this press release that are not
historical in nature constitute forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements
include, without limitation, statements regarding the future
development and efficacy of MN-166, MN-221, MN-001 and MN-029.
These forward-looking statements may be preceded by, followed by or
otherwise include the words "believes," "expects," "anticipates,"
"intends," "estimates," "projects," "can," "could," "may," "will,"
"would," “considering,” “planning” or similar expressions. These
forward-looking statements involve a number of risks and
uncertainties that may cause actual results or events to differ
materially from those expressed or implied by such forward-looking
statements. Factors that may cause actual results or events to
differ materially from those expressed or implied by these
forward-looking statements include, but are not limited to, the
risk that the CBOE may, in the future, stop listing options (calls
and puts) for MediciNova common stock, and the other risks and
uncertainties described in MediciNova's filings with the Securities
and Exchange Commission, including its annual report on Form 10-K
for the year ended December 31, 2015 and its subsequent periodic
reports on Forms 10-Q and 8-K. Undue reliance should not be placed
on these forward-looking statements, which speak only as of the
date hereof. MediciNova disclaims any intent or obligation to
revise or update these forward-looking statements.
INVESTOR CONTACT:
Geoff O'Brien
Vice President
MediciNova, Inc.
info@medicinova.com
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Sep 2023 to Sep 2024